Patent No. EP2912175 (titled "Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use Thereof") was filed by Toolgen Incorporated on Oct 23, 2013. The application was issued on Aug 22, 2018.
A composition for cleaving target DNA in eukaryotic cells or organisms using a CRISPR/Cas9 system. The composition comprises a guide RNA specific for the target DNA and Cas9 protein or Cas9 protein-encoding nucleic acid. It enables precise genome editing in eukaryotes by introducing double-strand breaks at desired locations using the RNA-guided Cas9 endonuclease. The composition can be used for genotyping mutations and variations in eukaryotic cells and organisms.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents